News
Sanofi builds case for Sarclisa, challenging J&J’s Darzalex
Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark
